Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prostate Cancer Combination Treatment Could Beat Disease at Its Own Game: Early Study

By Drug Discovery Trends Editor | April 30, 2015

Prostate cancer cellsWhen prostate cancer advances to the point of spreading, the larger and more stubborn tumors develop cells that suppress the body’s immune response – and defeat doctors’ attempts to launch an attack on it, experts said.

But through chemoimmunotherapy, a chemical one-two punch, a team of doctors said they are now having new success in mouse models. By first stripping the tumors of hijacked immunosuppressive B cells, and then using drugs to arm the immune system, researchers at the University of California – San Diego were able to nearly eradicate the tumors, they said.

“The presence of such B cells in human prostate cancer calls for clinical testing of this novel therapeutic approach,” said Shabnam Shalapour, the postdoctoral researcher who was the first author of the study.

Prostate cancer, if caught early, can be treated successfully. But once it develops to the point of metastasizing, it becomes significantly more deadly. If it spreads to the bone, the five-year survival rates plummet.

In the mouse models, the prostate tumors were all immune to oxaliplatin, which activates the immune system’s response to fight the cancerous cells. But when researchers blocked the development of the immunosuppressive B cells which were allowing the cancer to cloak itself, the tumors were attacked successfully, they said.

The UC – San Diego researchers said a similar two-pronged attack could prove successful with other types of cancer.

“In addition to prostate cancer, similar immunosuppressive B cells can be detected in other human cancers,” said Michael Karin, the school’s Distinguished Professor of Pharmacology and Pathology. “This indicates that B cell-mediated immunosuppression might be the reason several other cancers are also unresponsive to checkpoint inhibitors, raising the hope that chemoimmunotherapy will have broader applications for many cancer types.”

Prostate cancer is the second-deadliest cancer in American men. Some 1 in 7 will be diagnosed in their lifetime, and 1 in 38 overall will die of it. Some 27,540 died of the disease in 2015, according to the American Cancer Society.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE